Results for tag: "Spinal Muscular Atrophy Drug"

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and wasting. As a result, individuals with SMA experience difficulty with activities of daily living, such as walking, eating, and breathing. Treatment for SMA is focused on managing symptoms and slowing the progression of the disease. The SMA drug market is a subset of the Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological disorders, including SMA. Currently, there are several drugs approved for the treatment of SMA, including Spinraza, Zolgensma, and Evrysdi. These drugs are designed to slow the progression of the disease and improve the quality of life for those affected. Some of the companies in the SMA drug market include Biogen, Novartis, AveXis, and Roche. These companies are actively researching and developing new treatments for SMA, as well as providing access to existing treatments. Show Less Read more